Literature DB >> 30354694

Top-ranking drugs out of 3312 drug-induced liver injury cases evaluated by the Roussel Uclaf Causality Assessment Method.

Rolf Teschke1,2.   

Abstract

INTRODUCTION: A list presenting a valid ranking of drugs most commonly implicated is hardly to be found. Areas covered: Published cases of drug-induced liver injury (DILI) with verified causality using RUCAM (Roussel Uclaf Causality Assessment Method) were used for a ranking of drugs most commonly implicated in causing DILI. Expert opinion: RUCAM-based DILI cases were retrieved from 15 reports published by six international databases of DILI registries and three large medical centers, which provided 3312 cases. Overall 48 drugs with the highest number of DILI cases were listed. Among the top 10 ranking drugs implicated in causing DILI were, in decreasing order: amoxicillin-clavulanate, flucloxacilllin, atorvastatin, disulfiram, diclofenac, simvastatin, carbamazepine, ibuprofen, erythromycin, and anabolic steroids as bodybuilding agents. For these 10 drugs, respective DILI case numbers were highest for Amoxicillin-clavulanate (n=333) and lowest for anabolic steroids (n=26). The author classifies the databases of national DILI registries and large medical centers as best sources of drugs implicated in DILI. Presently discouraged is the use of the LiverTox website because many cases were derived from published cases of poor quality and could previously not be classified as DILI, calling for the inclusion of DILI cases with established causality by the updated RUCAM.

Entities:  

Keywords:  DILI registries; Drug-induced liver injury; Roussel Uclaf Causality Assessment Method; alternative causes; clinical DILI centers; herb-induced liver injury

Mesh:

Substances:

Year:  2018        PMID: 30354694     DOI: 10.1080/17425255.2018.1539077

Source DB:  PubMed          Journal:  Expert Opin Drug Metab Toxicol        ISSN: 1742-5255            Impact factor:   4.481


  14 in total

Review 1.  Strategies for Early Prediction and Timely Recognition of Drug-Induced Liver Injury: The Case of Cyclin-Dependent Kinase 4/6 Inhibitors.

Authors:  Emanuel Raschi; Fabrizio De Ponti
Journal:  Front Pharmacol       Date:  2019-10-24       Impact factor: 5.810

Review 2.  Mitochondrial stress response in drug-induced liver injury.

Authors:  Jing Zheng; Qiulin Yuan; Cao Zhou; Weifeng Huang; Xiang Yu
Journal:  Mol Biol Rep       Date:  2021-08-25       Impact factor: 2.316

Review 3.  Liver Injury in COVID-19 Patients with Drugs as Causatives: A Systematic Review of 996 DILI Cases Published 2020/2021 Based on RUCAM as Causality Assessment Method.

Authors:  Rolf Teschke; Nahum Méndez-Sánchez; Axel Eickhoff
Journal:  Int J Mol Sci       Date:  2022-04-27       Impact factor: 6.208

4.  Inhibition Activity of Avibactam against Nocardia farcinica β-Lactamase FARIFM10152.

Authors:  David Lebeaux; Clément Ourghanlian; Delphine Dorchène; Daria Soroka; Zainab Edoo; Fabrice Compain; Michel Arthur
Journal:  Antimicrob Agents Chemother       Date:  2020-01-27       Impact factor: 5.191

Review 5.  Mechanism of idiosyncratic drug induced liver injury (DILI): unresolved basic issues.

Authors:  Rolf Teschke; Jack Uetrecht
Journal:  Ann Transl Med       Date:  2021-04

Review 6.  Idiosyncratic Drug Induced Liver Injury, Cytochrome P450, Metabolic Risk Factors and Lipophilicity: Highlights and Controversies.

Authors:  Rolf Teschke; Gaby Danan
Journal:  Int J Mol Sci       Date:  2021-03-26       Impact factor: 5.923

Review 7.  PXR-mediated idiosyncratic drug-induced liver injury: mechanistic insights and targeting approaches.

Authors:  Jingheng Wang; Monicah Bwayi; Rebecca R Florke Gee; Taosheng Chen
Journal:  Expert Opin Drug Metab Toxicol       Date:  2020-06-16       Impact factor: 4.481

Review 8.  Idiosyncratic DILI: Analysis of 46,266 Cases Assessed for Causality by RUCAM and Published From 2014 to Early 2019.

Authors:  Rolf Teschke
Journal:  Front Pharmacol       Date:  2019-07-23       Impact factor: 5.810

Review 9.  Polygonum multiflorum-Induced Liver Injury: Clinical Characteristics, Risk Factors, Material Basis, Action Mechanism and Current Challenges.

Authors:  Yi Liu; Wenping Wang; Mingyi Sun; Baorui Ma; Linnuo Pang; Yuanyuan Du; Xiaoxv Dong; Xingbin Yin; Jian Ni
Journal:  Front Pharmacol       Date:  2019-12-13       Impact factor: 5.810

Review 10.  Diagnostic Biomarkers in Liver Injury by Drugs, Herbs, and Alcohol: Tricky Dilemma after EMA Correctly and Officially Retracted Letter of Support.

Authors:  Rolf Teschke; Axel Eickhoff; Amy C Brown; Manuela G Neuman; Johannes Schulze
Journal:  Int J Mol Sci       Date:  2019-12-27       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.